PRIMA BIOMED INITIATES PHASE IIB STUDY IN METASTATIC BREAST CANCER

PRIMA BIOMED PROGRESSES JAPANESE COLLABORATION

PRIMA BIOMED RECEIVES TAX REBATE FROM AUSTRALIAN GOVERNMENT

PRIMA BIOMED UNVEILS PHASE I COMBINATION STUDY OF IMP321 + CHECKPOINT INHIBITOR

PRIMA BIOMED WILL PRESENT AT THE ICI EUROPE MEETING IN GERMANY, NOVEMBER 16-18, 2015

PRIMA BIOMED GAINS BELGIAN REGULATORY APPROVAL TO COMMENCE A REGISTRATION PHASE IIB STUDY OF IMP321

PRIMA BIOMED RAISES A$1.55M THROUGH PLACEMENT TO SOPHISTICATED EUROPEAN HEALTHCARE INVESTOR

PRIMA BIOMED RECEIVES GRANT FROM THE SAXONY DEVELOPMENT BANK

PRIMA BIOMED ANNOUNCES COMMENCEMENT OF MILESTONES FOR IMP701 PROGRAM

PRIMA BIOMED TERMINATES INVESTMENT FACILITY WITH BERGEN GLOBAL OPPORTUNITY FUND, LP

Re: Results of 2015 Extraordinary General Meeting

Prima Biomed Ltd 2015 Extraordinary General Meeting

PRIMA BIOMED RAISES A$10M THROUGH SHARE PURCHASE PLAN

SHARE PURCHASE PLAN OFFER DOCUMENTS

PRIMA BIOMED RECEIVES POSITIVE SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY FOR ITS LEAD PRODUCT, IMP321

A MESSAGE FROM THE CHAIRMAN

PRIMA BIOMED RECEIVES A RESEARCH TAX CREDIT CASH REBATE IN FRANCE

PRIMA BIOMED TO MAINTAIN NASDAQ LISTING

PRIMA BIOMED ANNOUNCES NEW IP FOR ITS LEAD IMP321 DEVELOPMENT PROGRAM

PRIMA BIOMED TO COMMERCIALISE CVAC’S DATABASE MANAGEMENT PLATFORM WITH DATABASE INTEGRATIONS INC. (DBI)

CVAC SHOWS OVERALL SURVIVAL BENEFIT IN SECOND REMISSION OVARIAN CANCER IN PHASE II STUDY

PRIMA BIOMED ANNOUNCES A$15 MILLION INVESTMENT FROM US HEALTHCARE INVESTOR RIDGEBACK

PRIMA BIOMED ANNOUNCES JAPANESE COLLABORATION

PRIMA BIOMED TO PRESENT AT CANARY NETWORKS’ BIOTECH AND HEALTHCARE INVESTOR ROADSHOW

PRIMA BIOMED PRIORITISING IMP321

FINANCIAL MILESTONE PAYMENT TO BE RECEIVED FROM GSK

$777K R&D TAX INCENTIVE REFUND RECEIVED

PRIMA BIOMED APPOINTS GLOBAL HEAD OF INVESTOR RELATIONS